Morgan Stanley has recently updated its price target for Adaptive Biotechnologies (ADPT, Financial), raising it from $7.00 to $9.00 per share. This adjustment represents a significant increase of 28.57% in the stock's price target.
The update was issued by analyst Tejas Savant on May 5, 2025. Despite the increase in the price target, the rating for Adaptive Biotechnologies (ADPT, Financial) remains at "Equal-Weight," consistent with the previous assessment.
This reflects Morgan Stanley's view that the current market price of Adaptive Biotechnologies (ADPT, Financial) may still perform in line with other stocks in the industry, despite the revised price target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Adaptive Biotechnologies Corp (ADPT, Financial) is $11.00 with a high estimate of $13.00 and a low estimate of $9.00. The average target implies an upside of 13.99% from the current price of $9.65. More detailed estimate data can be found on the Adaptive Biotechnologies Corp (ADPT) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Adaptive Biotechnologies Corp's (ADPT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Adaptive Biotechnologies Corp (ADPT, Financial) in one year is $8.34, suggesting a downside of 13.58% from the current price of $9.65. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Adaptive Biotechnologies Corp (ADPT) Summary page.
